Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4788121 | 0.83 | PTP4A1 (0.47) | PTPN1PTPN2PTPN6ALDH1A1KDM4E | |
| SCHEMBL31487946 | 0.82 | HPGD (0.50) | ALDH1A1PTGS2KDM4EMAPK1POLB | |
| SCHEMBL9287591 | 0.82 | HPGD (0.50) | ALDH1A1PTGS2KDM4EMAPK1POLB | |
| SCHEMBL21712025 | 0.82 | KDM4E (0.44) | ALDH1A1PTGS2KDM4EGAAMAPK1 | |
| SCHEMBL3308517 | 0.81 | ALDH1A1 (0.44) | PTPN1ALDH1A1PTGS2KDM4EGAA | |
| SCHEMBL4756891 | 0.80 | ALDH1A1 (0.49) | ALDH1A1PTGS2KDM4EGAAERN1 | |
| SCHEMBL5778489 | 0.80 | ALDH1A1 (0.43) | ALDH1A1PTGS2KDM4EGAACA12 | |
| SCHEMBL4756919 | 0.79 | PTPN1 (0.69) | PTPN1PTPN2PTPN6ERN1 | |
| SCHEMBL31497642 | 0.79 | PTPN1 (0.69) | PTPN1PTPN2PTPN6ERN1 | |
| SCHEMBL17627594 | 0.79 | AKR1C4 (0.60) | ALDH1A1KDM4EGAAMAPK1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879661-A1 | AGENT FOR DYEING KERATIN-BASED FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2008-01-23 | — | — | EP | claimed |
| WO-2006119821-A1 | AGENT FOR DYEING KERATIN-BASED FIBRES | HENKEL KOMMANDITGESELLCHAFT AUF AKTIEN (DE) | 2006-11-16 | — | — | WO | claimed |
| US-12577227-B2 | WDR5 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| US-20220242849-A1 | WDR5 INHIBITORS AND MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-08-04 | — | — | US | disclosed |
| WO-2020247679-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY (US) | 2020-12-10 | — | — | WO | disclosed |
| US-8034945-B2 | 4-phenyl-5-OXO-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility | N.V. ORGANON (NL) | 2011-10-11 | — | — | US | disclosed |
| EP-1879580-B1 | 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF INFERTILITY | ORGANON NV (NL) | 2009-03-11 | — | — | EP | disclosed |
| US-20080300270-A1 | 4-Phenyl-5-Oxo-1,4,5,6,7,8,- Hexahydroquinoline Derivatives as Medicaments for the Treatment of Infertility | MERCK SHARP & DOHME B.V. (NL) | 2008-12-04 | — | — | US | disclosed |
| EP-1879580-A1 | 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF INFERTILITY | N.V. Organon (NL) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117370-A1 | 4-PHENYL-5-OXO-l,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF INFERTILITY | N.V. ORGANON (NL) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242849-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | PTPN1 3135/4885PTPN2 3280/4885PTPN6 3029/4885 |
| US-12577227-B2 | WDR5 inhibitors and modulators | WDR1, WDR5, WDR3 | PTPN1 1847/4885PTPN2 2549/4885PTPN6 2052/4885 |
| US-20080300270-A1 | 4-Phenyl-5-Oxo-1,4,5,6,7,8,- Hexahydroquinoline Derivatives as Medicaments for the Treatment of Infertility | FSHR, GNRHR, LHCGR | PTPN1 2512/4885PTPN2 2935/4885PTPN6 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.